Rossen Kazakov
Rossen Kazakov has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Susan Howick
University of Strathclyde
2 shared publications - Alec Morton
Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore
1 shared publication - Bernd Wurth
Strathclyde Business School
1 shared publication - Itamar Megiddo
Department of Management Science, University of Strathclyde, Glasgow, UK
1 shared publication - Le Khanh Ngan Nguyen
University of Strathclyde
1 shared publication M Kunc
Warwick Business School Coventry UK
1 shared publication
Latest Publications
- 23 August 2024
- Published by Springer Nature
- p. 213-244
Combining SD and ABM: Frameworks, Benefits, Challenges, and Future Research Directions
- 23 August 2024
- Published by Springer Nature
- p. 213-244
Combining SD and ABM: Frameworks, Benefits, Challenges, and Future Research Directions
- 1 April 2021
- Published by Elsevier in European Journal of Operational Research
- Vol. 290 (1) , 386-400
Managing complex adaptive systems: A resource/agent qualitative modelling perspective
- 1 April 2021
- Published by Elsevier in European Journal of Operational Research
- Vol. 290 (1) , 386-400
Managing complex adaptive systems: A resource/agent qualitative modelling perspective
- Open Access
- 5 October 2015
- Published by Taylor & Francis in Journal of Pharmaceutical Policy and Practice
- Vol. 8 (S1) , P17
Reimbursement policy optimization for Angiotensin-converting enzyme (ACE) inhibitors in Bulgaria: Controlling expenditure without undermining access to treatment
Submit your next manuscript to BioMed Central and take full advantage of: • Convenient online submission • Thorough peer review • No space constraints or color figure charges • Immediate publication on acceptance • Inclusion in PubMed, CAS, Scopus and Google Scholar • Research which is freely available for redistribution
- 5 October 2015
- Published by Taylor & Francis in Journal of Pharmaceutical Policy and Practice
- Vol. 8 (S1) , P17
Open AccessReimbursement policy optimization for Angiotensin-converting enzyme (ACE) inhibitors in Bulgaria: Controlling expenditure without undermining access to treatment
Submit your next manuscript to BioMed Central and take full advantage of: • Convenient online submission • Thorough peer review • No space constraints or color figure charges • Immediate publication on acceptance • Inclusion in PubMed, CAS, Scopus and Google Scholar • Research which is freely available for redistribution
- 26 May 2015
- Published by Springer Nature in Systemic Practice and Action Research
- Vol. 29 (1) , 1-25
Foreseeing the Dynamics of Strategy: An Anticipatory Systems Perspective
- 26 May 2015
- Published by Springer Nature in Systemic Practice and Action Research
- Vol. 29 (1) , 1-25
Foreseeing the Dynamics of Strategy: An Anticipatory Systems Perspective
- 21 December 2013
- Published by Taylor & Francis in Journal of the Operational Research Society
- Vol. 64 (12) , 1790-1799
Competitive dynamics in pharmaceutical markets: A case study in the chronic cardiac disease market
- 21 December 2013
- Published by Taylor & Francis in Journal of the Operational Research Society
- Vol. 64 (12) , 1790-1799
Competitive dynamics in pharmaceutical markets: A case study in the chronic cardiac disease market
- 1 July 2007
- Published by SAGE Publications in Journal of Generic Medicines
- Vol. 4 (4) , 249-258
Pricing and Reimbursement Policies in New EU Accession Countries
This paper aims to provide an informative and analytical view on healthcare policies on pricing and reimbursement in new accession countries, their reflection by the new national drugs legislations, and pricing and reimbursement policies, constraints and opportunities for the EU generic medicines producers. It is driven by the belief that having a greater understanding will help the pricing and reimbursement strategy planning process, and will enhance companies' performance while achieving greater awareness of the influence of the health policy factors in the region. A major stress is put on the process of change and the need for reformation of the healthcare policies on pricing and reimbursement, coming out of the EU enlargement process and legislation harmonisation. A snapshot is given of current pricing and reimbursement models together with a look at the Central and Eastern Europe drugs markets recent figures. Cost containment measures like economic evaluation of drugs, cross-countries price comparisons and parallel trade, and the slide from a branded to unbranded generics market are highlighted as the major factors that generic companies should take into account in the near future.
- 1 July 2007
- Published by SAGE Publications in Journal of Generic Medicines
- Vol. 4 (4) , 249-258
Pricing and Reimbursement Policies in New EU Accession Countries
This paper aims to provide an informative and analytical view on healthcare policies on pricing and reimbursement in new accession countries, their reflection by the new national drugs legislations, and pricing and reimbursement policies, constraints and opportunities for the EU generic medicines producers. It is driven by the belief that having a greater understanding will help the pricing and reimbursement strategy planning process, and will enhance companies' performance while achieving greater awareness of the influence of the health policy factors in the region. A major stress is put on the process of change and the need for reformation of the healthcare policies on pricing and reimbursement, coming out of the EU enlargement process and legislation harmonisation. A snapshot is given of current pricing and reimbursement models together with a look at the Central and Eastern Europe drugs markets recent figures. Cost containment measures like economic evaluation of drugs, cross-countries price comparisons and parallel trade, and the slide from a branded to unbranded generics market are highlighted as the major factors that generic companies should take into account in the near future.
- 1 June 2007
- Published by SAGE Publications in Journal of Medical Marketing: Device, Diagnostic and Pharmaceutical Marketing
- Vol. 7 (3) , 245-253
Between strategy and change: Reformulating the medicines industry in an enlarged Europe
The question as how to achieve competitive advantage through a genuine and innovative set of strategic principles and tools is ever present in the business repertoire of all industries. Yet few manage to reorder their way of doing things to achieve the perfect correlation between business goals and external customers' expectations. With modern economics rejecting the existence of a perfect equilibrium between supply and demand, the job of the business strategy planner is harder than never before. The key to successful strategy creation, as this paper shows, lies in an understanding of three strategic perspectives:
- 1 June 2007
- Published by SAGE Publications in Journal of Medical Marketing: Device, Diagnostic and Pharmaceutical Marketing
- Vol. 7 (3) , 245-253
Between strategy and change: Reformulating the medicines industry in an enlarged Europe
The question as how to achieve competitive advantage through a genuine and innovative set of strategic principles and tools is ever present in the business repertoire of all industries. Yet few manage to reorder their way of doing things to achieve the perfect correlation between business goals and external customers' expectations. With modern economics rejecting the existence of a perfect equilibrium between supply and demand, the job of the business strategy planner is harder than never before. The key to successful strategy creation, as this paper shows, lies in an understanding of three strategic perspectives: